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Péter Molnár 
University of Debrecen, Medical and Health Sciences Center, Department of Pathology 
Hungary 
1. Introduction 
The guiding principle of this chapter is the importance of combining traditional 
morphological data with the recently acquired knowledge on the genetic and epigenetic 
signalling pathways which drive the evolution of CNS tumors. The official World Health 
Organization terminology (WHO, 2007) will be used since it is the source of information for 
neurooncology, neuroradiology, neurosurgery, etc. It is of outmost importance that new 
entities have emerged since 2007 and it seems inevitable to see a new classification in the 
near future. It is beyond the scope if this chapter to dwell on the pitfalls in diagnostic 
surgical neuropathology, suffice is to say that the classic, traditional case descriptions which 
are usually presented in textbooks comprise only a fraction of diagnostic dilemmas so often 
hunting practicing neuro-oncopathologists. 
The main focus will be placed on intracranial lesions but it needs to be emphasized that the 
diagnostic entities which come the way of a surgical neuropathologist broadly overlap with 
an extensive range of entities which basically belong to hematopathology, soft tissue and 
bone/chondroid tumors. 
In all textbooks on neuropathology the usual way to start is to point out that knowledge of 
brain and spinal cord anatomy as well as familiarity with the broad range of cellular 
reactions in diseased CNS are essential for success in understanding pathology reports. 
There is no way to cover all these details, hence a list of reference books is provided. This 
chapter is born out of the need to outline unambiguous and consistent terminology of brain 
tumors. This together with a strong urge to define the use of a universally accepted grading 
system (be that weak as it is despite of century-old efforts) could help not only all specialists 
who are involved in treating brain tumor patients but also and of outmost importance the 
patients themselves. 
2. Pathology of brain tumors – A general overview 
Brain tumors are not that common (about 1-1.5% of neoplasms in adults) but they still 
present an often frustrating challenge for oncologists even in developed countries. In 
contrast to the somewhat limited pathologic variations of adult brain tumors the extreme 
phenotypic diversity of pediatric brain tumors often results in overwhelming diagnostic 
problems even for the experienced pediatric pathologist. A recent report from France states 
that over 5 years, 25 756 cases of newly diagnosed and histologically confirmed primary 
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CNS tumors (PCNST) have been recorded. Histological diagnoses included glioma 48.9%, 
all other neuroepithelial tumors 5%, meningioma 28.8%, nerve sheath tumor 8.4%, 
lymphoma 3.2% and others 5.7%. 
Epidemiological data on the most common intracranial tumors are presented in Table 1. The 
data are from the 2011 CBTRUS Statistical Report (http://www.cbtrus.org/2007-2008/2007-
20081.html.) 
 
Tumor type Gradea Incidenceb Male/Female 
5-year-
survival (%)c 
Pilocytic 
astrocytoma 
I 0.27 1.0 94 
Diffuse astrocytoma II 0.15 1.2 48 
Anaplastic 
astrocytoma 
III 0.48 1.4 27 
Glioblastoma IV 2.60 1.6 5 
Oligodendrogliomad II/III 0.38 1.5 80 
Ependymoma II/III 0.24 1.4 82 
Medulloblastoma IV 0.26 1.6 62 
Meningeomae I (II/III) 0.75 0.5 67 
a: WHO 2007; b: New case/1 million population/year (1995-2007, CBTRUS; USA); c: observed chance of 
survival compared to the expected life span („survival”) of the reference population (USA). SEER 
(Survival, Epidemiology and End Results) 2010. d. The five-year-long survival of anaplastic 
oligodendrogliomata is 49%. e. Intracranial and spinal meningeomata combined. 
Table 1. 
The direct cause of brain tumors is largely unknown. Inherited tumor-syndromes have 
helped to shed light on various genetic abnormalities which might play a role in tumor-
induction. It is well documented that radiation of the head-and-neck region is associated 
with an increasing number of meningiomas. Primary CNS lymphomas (PCNSLs) are the 
most common causes of non-infective intracranial space occupying lesions in immuno-
compromised people. The frequency of PCNSL has increased almost by an order of a 
magnitude (3-10x) and this tendency is present among those with normal immune system. 
An increased incidence of gliomas has become obvious by the last decade of the 20th 
century, and this is not due to the advanced sensitivity of diagnostic tools. 
Although in most cases the etiology of neoplastic transformation awaits clarification there 
has been a truly revolutionary explosion of genetic and molecular tools giving new 
information that has fundamentally changed both basic and translational (clinical) neuro-
oncology. Analysis of genetic instability and basic data on invasion and angiogenesis have 
all became inescapable questions to pursue during routine diagnostic activity. Information 
on gene expression profiles, application of tissue microarray techniques, follow up on 
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mRNA splicing patterns, are now considered to be part of the state-of-the-art workup in 
brain tumor analysis. These inevitably depend on functional genomics and bioinformatics. It 
is fair to say that the last 2-3 years have fundamentally changed our concept of diagnostic, 
prognostic and predictive markers in neuro-oncology.  
All these changes require a new attitude towards tissue samples: the neurosurgeon must be 
aware of the importance of sampling that will critically influence the pathologist’s ability to 
outline the major aspects of tailored therapy. Hence it cannot be overemphasized that the 
decisions on the distribution of various parts of a biopsy between diagnostic labs and research 
areas (including tumor banks) are the sole and outmost responsibility of the pathologist. This 
is the only way to ensure that the Hippocratic requirement of “Salus aegroti suprema lex esto1” is 
realized. No academic goal may interfere with the proper, individual, personalized diagnosis!  
The precise diagnosis (both radiological and pathological) of brain tumors is significantly 
dependent on the fact that certain entities are linked with specific geographical areas 
(anatomical locations) within the CNS. Similarly, age does have an almost pathognomonic 
relevance in most cases. As always, exceptions to this fundamental rule are not infrequent, 
still it is the combined knowledge of radiological characteristics, exact site of the lesion and 
the patient’s age which is an indispensible guidance for the pathologist. 
2.1 Histological classification of various tumor types affecting the central nervous 
system 
It is mentioned above that the last WHO classification was published in 2007. Since then 
new entities have been recognized. The idea that the pattern of differentiation is reflected by 
phenotypic features (in other words, phenotype may give a clue about the cell of origin) has 
been retained in the WHO classification. Despite of a long-lasting dispute it has not been 
fully decided whether “retrogressive” differentiation (loss of maturity from a mature state) 
can or cannot result in cancer formation. Meanwhile it has become generally accepted that 
tumors most often arise from “cancer stem cells”. The term tumor initiating cells (TICs) 
probably describes best the features of these progenitor elements which are assumed to be 
capable of self-renewal and of divergent differentiation. It is worth noting here that these 
“stem cells” are hypothesized to strongly interact with their immediate micromilieau 
(niche). As a result the actual TICs’ behavior and chemo- and/or radioresistance will be 
modified by the niche elements (endothelial cells, microglia, concentration of various 
signalling molecules, etc.). This explains why these cells which are often of low proliferative 
activity can maintain tumor growth or recurrence after vigorous treatment.  
Table 2. is construed basically on the WHO 2007 classification with some modifications. It is 
important for oncologists to be aware of new entities which most likely will be included in 
the next WHO book and already occur in pathology reports. It must repeatedly be stressed 
that the frequency, location and types of CNS tumors vary with age and to some degree 
with sex. The largest group of tumors comprises neuroepithelial neoplasms, a significant 
portion of intracranial tumors are meningeal and metastatic lesions. Gliomas (astrocytomas, 
oligodendrogliomas and ependymomas) account for circa 40% of all tumors and 
approximately 80% of malignant tumors. The most comprehensive and up-to-date 
information on the epidemiology of various CNS tumors is available on the CBTRUS 
website shown above. 
                                                                 
1 In a rather free translation: „Everything is to serve the best interest of the patient.” 
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I. Neuroepithelial tumors 
a. Astrocytic tumors 
Pilocytic astrocytoma 
Pilomyxoid astrocytoma 
Pleomorphic xanthoastrocytoma 
Diffuse astrocytomas 
Anaplastic astrocytoma 
Glioblastoma 
Glioblastoma with significant oligodendroglial component (GBO) 
Giant cell glioblastoma 
Gliosarcoma 
Gliomatosis cerebri 
b. Oligodendroglial tumors 
Oligodendroglioma 
Anaplastic oligodendroglioma 
Oligoastrocytoma 
Anaplastic oligoastrocytoma 
c. Ependymal tumors 
Ependymoma 
Anaplastic ependymoma 
Myxopapillary ependymoma 
Subependymoma 
d. Choroid plexus tumors 
Choroid plexus papilloma 
Atypical choroid plexus papilloma 
Choroid plexus carcinoma 
e. Other neuroepithelial tumors 
Astroblastoma 
Chordoid glioma of the third ventricle 
Angiocentric glioma 
II. Neuronal and mixed neuronal-glial tumors 
a. Neuronal tumors 
Gangliocytoma and ganglioglioma 
Dysplastic gangliocytoma of the cerebellum 
Central neurocytoma and variants 
b. Mixed neuronal-glial tumors 
Ganglioglioma 
Anaplastic ganglioglioma 
Desmoplastic infantile astrocytoma and ganglioglioma (DIA/DIG) 
Central neurocytoma and extraventricular neurocytoma 
Cerebellar liponeurocytoma 
Papillary glioneural tumor (PGNT) 
Rosette-forming glioneural tumor of the 4th ventricle (RGNT) 
Paraganglioma (spinal) 
Dysembryoplastic neuroepithelial tumor 
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III. Tumors of the pineal region 
Pineocytoma 
Pineal parenchymal tumor of intermediate differentiation 
Pineoblastoma 
Papillary tumor of the pineal region 
IV. Tumors of the sellar region 
Pituitary adenoma 
Craniopharyngeoma 
Granular cell tumor of the neurohypophysis 
Pituicytoma 
Spindle cell oncocytoma of the adenohypophysis 
V. Embryonal tumors 
Medulloblastoma 
Classical medulloblastoma 
Desmoplastic/nodular medulloblastoma 
Medullomyoblastoma 
Melanotic medulloblastoma 
CNS primitive neuroectodermal tumor (cPNET) 
Medulloepithelioma 
Ependymoblastoma 
Atypical rhabdoid/teratoid tumor (AT/RT) 
VI. Tumors of the cranial nerves 
Schwannoma (Neurilemmoma) 
Neurofibroma 
Perineurioma 
Malignant peripheral nerve sheath tumor (MPNST) 
VII. Meningeal tumors 
Meningiomas 
Mesenchymal, non-meningothelial tumors 
Hemangiopericytoma 
Melanotic lesions 
Hemangioblastoma 
VIII. Tumors of the hemopoietic system 
Malignant lymphomas 
Histiocytic tumors 
IX. Germ cell tumors 
CNS germ cell tumors 
X. Familial tumor syndromes 
Neurofibromatosis type I. (NF1) 
Neurofibromatosis type II. (NF2) 
Schwannomatosis 
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von Hippel-Lindau disease and haemangioblastoma 
Tuberous sclerosis complex and subependymal giant cell astrocytoma (SEGA) 
Lhermitte-Duclos disease 
Cowden disease and dysplastic gangliocytoma of the cerebellum 
Turcot syndrome 
Li-Fraumeni syndrome and TP53 germline mutations 
Rhabdoid tumor predisposition syndrome 
Naevoid basal cell carcinoma syndrome 
XI. Metastatic tumors of the CNS 
Table 2. 
The various names date back to the first comprehensive classification of nervous system tumors 
put together by Percival Bailey and Harvey Cushing in 1926. This was based on presumed 
parallels between embryologic cell forms and neoplastic elements. This nomenclature is still in 
use, however much of the terminology has changed fundamentally.  
Neoplasia is a genetic disease and now there is abundant information at hand about alterations 
which occur in key regulatory genes, either inherited in mutant forms or arising sporadically as 
a result of somatic noxae to growth regulatory genes. Tumors may come about when the 
function of protein products of key growth regulatory genes is altered or they can develop as a 
result of random genetic changes which are not properly corrected by DNA repair mechanisms. 
As it is shown in Fig. 1. current hypotheses drastically overwrite our previous concepts about 
the origin of neoplastic cells. It has for a long time been held that terminally differentiated cells 
are incapable to form neoplasms. Recent observations indicate that non-canonical steps, like 
epithelial-mesenchymal transformation (EMT) or the reverse (MET) may be involved in 
tumorigenesis and metastatic spread of cancer. In light of these data the hypothetical routes 
(indicated by dashed lines in the Figure 1) of regressive differentiation become easier to 
comprehend. This scenario is being actively researched and doubtlessly important role is 
allocated to cells with pluripotency in the evolution of brain tumors. NB. These cells are often 
referred to as tumor stem cells, although they do not necessarily fulfill the requirements of bona 
fide stem cells. Figure 1 also shows that there is no common understanding of how ependymal 
tumors fit into this hypothesis, neither it is clear how exactly mixed glial tumors evolve. The 
latter phenomenon might be related to clonal selection during the accumulation of genetic 
damage as tumors progress. In this biological, pathological sense tumor progression is strictly 
related to dedifferentiation (i. e., increasing grade) and not to the change of total tumor volume, 
as it is often used in clinical, particularly radiological terminology. Cellular heterogeneity and 
the almost inevitable progression (accumulation of genetic abnormalities inducing 
dedifferentiation) are paramount intrinsic features of glial tumors. 
The detailed description of histological and cellular features of individual tumor types 
defies the length of this chapter. Moreover, neither neurosurgeons, nor neuro-oncologists 
are benefiting from these textbook data. However, if an individual tumor carries unusual 
features and still needs to be squeezed in an existing category (mainly because health 
insurance policies often require traditionally “boxed” entities), it is the responsibility of the 
MDT to come to an agreement about a category which is suitable to fit in treatment 
protocols. Furthermore, descriptive analysis is bound to be enriched by individualized 
genetic and molecular data which eventually might carry more relevant information vis-á-
vis treatment than the classical histo- and cytopathologic characteristics (vide infra). 
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Fig. 1. Origin of neuroglial tumors. Modified after Huse JT and Holland EC. Nature Reviews 
Cancer doi:10.1038/nrc2818. 
2.2 Grading of CNS tumors 
The WHO classification grades tumors according to their malignant potential on a scale 
ranging from 1 for “benign” tumors to 4 for the most aggressive and malignant ones. Other 
grading systems have been used in the past, but the WHO 2007 system is now the one which 
is the most easy to find and is the one best recognized by pathologists, radiologists, 
neurosurgeons and oncologists. Modifications of the Kernohan system of grading were 
adopted by the WHO ever since the publication of the first “blue book” (1979). It was first 
revised in 1993, then in 2000 and 2007. It is very important to keep in mind that grading 
criteria are always artificial, arbitrary and despite of all world-wide efforts to avoid it, are 
always very subjective. Various techniques of the ever growing field of molecular 
diagnostics are increasingly employed not only in tumor classification but also in tumor 
grading. At this day and age it is still prudent to state that morphologic findings endure as a 
golden standard for proper evaluation of genetic and molecular observations. 
The original concept of grading was introduced by Broders who first realized that the 
degree of cellular differentiation does have a reliable value in predicting the biological 
behavior of cancerous growths of the lip. He hypothesized that the “cell-of-origin” model 
reflects clinical prognosis: if more than 75% of the cells are “like” the cell of origin (i. e., 
stratified squamous epithelium) indicating that the neoplastic elements retain significant 
degree of differentiation then the outlook is favorable. Since it proved to work well for a 
host of systemic cancers Kernohan introduced the idea to brain tumor analysis and 
suggested a four-tier grading model. 
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Four-tier grading scheme
Grade 1 Low proliferative potential and possibility of surgical cure 
Well-
differentiated 
Grade 2 Diffuse growth, tendency to recur, though only few mitoses 
Moderately-
differentiated 
Grade 3 
Histological evidence of malignancy, destructive growth, brisk 
mitotic activity, anisonucleosis
Poorly-
differentiated 
Grade 4 Cytologically malignant, mitotically active, necrosis-prone Anaplastic 
Eventually it has become increasingly obvious that the 4-tier-grading can be applied only 
with significant difficulties even to astrocytic tumors. Ringertz then applied a 3-tiered 
scheme for astrocytomas. 
 
Three-tier grading scheme
Grade 1 Low grade Well-differentiated
Grade 2 Intermediate grade Moderately differentiated
Grade 3 High grade Poorly-differentiated
This was replaced by the St.Anne/Mayo classification which was doomed because of the 
inclusion of a rather elusive and rarely occurring “Grade I.” lesion: diffuse astrocytic tumors 
without atypia. The current concept holds that Grade I. astrocytomas are relatively 
circumscribed (sic!), while all other grades by definition comprise diffusely growing tumors. 
It is obvious from the 2007 WHO classification that certain tumors have only 3 grades, 
however, the “missing” 4th category may be at the origo of the scale (ependymal, 
oligodendroglial, or mixed glial tumors) and thus the highest (most malignant) grade is Gr. 
III., which implies that a Gr. III. oligoastrocytoma (OA Gr. III.) often presents all cytological 
and histological features of the most malignant (Gr. IV.) astrocytoma, i. e., glioblastoma 
(GBM). Needless to say this often results in confusion, particularly for the oncologist whose 
decision on therapy is often highly determined by bureaucratic regulations (e. g., financial 
limitations of treatment options). To complicate issues further several tumors do not have 
Grade I. forms at all (oligoastrocytic tumors, OAs), while some Gr. I. lesions are strictly 
related to anatomic location (myxopapillary ependymoma or subependymal giant cell 
astrocytoma [SEGA]). A firm understanding of the meaning and significance of numerical 
grading among all people (usually members of the MDT = multidisciplinary team) is 
quintessential, particularly since the criteria used for assigning diagnoses and grades are 
different between the various systems in use, sometimes even between the older and newer 
WHO classifications. Numerical grades do not surmount the need for a fundamental 
understanding of the histological/cytological criteria for diagnosis of specific types of 
tumors. 
It is important to note that the definition of biological malignancy as reflected by increasing 
dedifferentiation is not necessary for lethal clinical outcome of a tumor. A highly 
differentiated meningeal tumor (Gr. I.) may kill a patient if it mechanically compresses vital, 
eloquent areas (meningioma of the edge of the foramen magnum). By the same token, the 
general principle of oncology that states that the most important indication of malignancy is 
metastatic spread does not hold in neuro-oncology. Even GBMs, which are considered to be 
the most malignant forms of gliomata rarely metastasize outside CNS compartments. 
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Table 3. summarizes the currently defined WHO grades within the most common CNS 
tumors. As a general rule staging is not applicable to CNS tumors and grading of non-CNS 
specific tumors can be found in the proper volume of the WHO series as well as in the 7th 
Edition of Cancer Staging Handbook. Neither Table 2. nor Table 3. go into details of various 
subtypes of primary and/or secondary CSN tumors. Everyone should keep in mind that 
chondrogenic, osteogenic, fibroblastic, etc. tumors may affect the brain or spinal cord either 
when arising de novo within the intracranial or intraspinal compartments or when they 
directly invade CNS tissue from adjacent structures. Their grading (and staging, for that 
matter) follows the general principles of systemic pathology. It is noteworthy, however, that 
the tight and non-compliant intracranial space poses additional biological/clinical problems 
in the latter cases: increased ic. pressure, brain herniation, etc. complicate treatment of these 
neoplasms. 
2.3 Limitations of morphological grading 
To demonstrate the subjectivity of glioma grading it is worth comparing the features of 
pilocytic tumors (as listed in the WHO fascicle) with those of GBMs. While doing so two 
definitions need to be taken into account. The highest glioma grade is assigned to tumors 
which have either endothelial proliferation and/or necrosis in the neoplasm. “Endothelial 
proliferation” nowadays is more often replaced by “MVP” (=microvascular proliferation). 
This phenomenon means not solely apparent multilayering of endothelial cells but a 
complex process that comprises endothelial atypia, endothelial mitotic activity (often 
accompanied by abnormal p53 immunohistochemical abnormalities, vide infra), and 
endothelial cell (EC) multiplication accompanied by an abnormal deposition of basal lamina 
(BL) components plus proliferative activity of pericytic elements. This often results in the 
formation of literally “glomerulum2”-like elements (glomeruloid proliferation), but the latter 
is not a sine qua non of Gr. IV. Not infrequently these abnormal vascular structures occur 
along the edge of the infiltrative zone or partially surrounding necrotic areas 
(“vasocorona”). Necrosis is another histological feature which often indicates malignant 
potential. This is not necessarily an indication of the parenchyma’s outgrowing the blood 
supply (as general pathology often states). Glial tumors are known to be very vascular but a 
heretofore unclarified complex dysregulation results in what is called “sui generis” tumor 
necrosis. The fundamental pathobiology of this phenomenon exceeds the limits of this 
chapter, it suffices to say that this necrosis (surrounded by palisading tumor cells) is 
fundamentally different from the “garden variety” infarctions. The latter are also common, 
since despite of rich neovascularization blood supply to gliomas is often interrupted by 
thromboses which may affect all sized vessels. 
Daily experiences firmly indicate that there is a myth surrounding numerical grades 
particularly since the problem usually is presented in almost all textbooks in a way that 
suggests: criteria are strict, obvious, and “self-evident” and their use is only a matter of 
routine. The following paragraphs are intended to shed light on the complexity of the issue. 
First I will quote from the last WHO book those sentences which describe features of 
pilocytic tumors which are the prime examples of a grade I. tumor (WHO 2007, pp15-20). It 
is worth to think through these quotations keeping in mind what almost everybody 
considers as prima facie evidence of the worst grade, i. e., glioblastoma. 
                                                                 
2 The “magic” capillary structure that occupies the Bowman space. 
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“…hyperchromatic and pleomorphic nuclei, glomeruloid vascular proliferation, infarct-like necrosis 
and infiltration of leptomeninges are compatible with the diagnosis of pilocytic astrocytoma”; 
“….degenerative atypia with pleomorphism, smudgy chromatin, and nuclear-cytoplasmic 
pseudoinclusions (are) frequently seen in long-standing lesions”; “enfilades resemble those of what 
was termed the ‘primitive polar spongioblastoma’ (may occur)”; “one study found the acquisition of 
atypia, particularly of increased cellularity and occasional mitoses, to be of no prognostic 
significance”. – It is also noted that pilocytic astrocytoma may undergo malignant transformation: 
“They often feature multiple mitoses per single high power field, endothelial proliferation and 
palisading necrosis. Such tumors should not be designated glioblastoma…” – given all these 
statements from the “horse’s mouth” (i. e., the most authoritative book on CNS tumors) it is 
not surprising that unless there is a firm understanding of the complexity of issues at hand 
oncologists often are dumbfounded when having read the descriptive part of a report they 
expect the worst (Gr. IV.) still they are given the best (Gr. I.) possible diagnosis. How is that 
possible? 
One should keep in mind that morphological evaluation is not a black-or-white type of 
decision forming intellectual activity; it is an analogous thinking process. Pathologists 
compare a waste amount (in fortunate situations) of mentally stored images to the actual 
fields in the microscope, they compare images-to-images, complex patterns to complex 
patterns and then put everything in context (age, sex, imaging features, intraoperative 
findings, macroscopic features, etc.) – provided they do have all this information. Anyone 
familiar with the image below can decide how objective and reliable analogous thinking is: 
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The dilemma is more obvious if one considers the proverbial pathologist’s answer to the 
clinicians’ question: Why is the diagnosis “this” and not “that”? – Because it looks more like “this” 
than “that”! And it does not mean that the pathologist is incompetent, the problem is 
inherent in the psychophysiology of “analogous thinking”. There is nothing else that would 
emphasize MDT work’s importance more than realization of this theoretical problem. 
To drop another stone into the seemingly quiet pond: there are physical limitations as well, 
namely, sampling errors. This is demonstrated (in an analogous way) with the help of the 
following images, which show two sides of the same apple from my kitchen table: 
 
 
Obviously often the pathologist does not have a chance to evaluate the whole lesion, in 3D, 
from all aspects. He is absolutely dependent upon the guidance of the neuroradiologist 
(who may be able to grade tumours in vivo [see Jakab et al]) and the neurosurgeon. 
Unfortunately the latter’s freedom of sampling is often highly limited and that complicates 
issues further: 
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The blue arrows indicate the variability and often non-representative nature of sampling. 
Imagine the inherent errors in grading when comparing the 3 biopsies from the same apple 
(“tumor”). Added to the problem is the almost pathognomonic regional heterogeneity of 
gliomas, particularly of high grade astrocytic tumors. Any neuro-oncopathologist who 
regularly diagnoses glioma samples could without any specific effort take a series of 
microphotographs from a GBM demonstrating tumor grades from I through IV. 
So, what is the conclusion? Can anyone trust pathologists for any degree of reliability? The 
answer is yes, but with adjuncts. Unless one is asking for legal and/or ethical problems 
should only give an opinion only if she or he is convinced that all necessary information is 
provided plus no part of the tissue has been retained (for scientific reasons or tissue 
banking). It is the prerogative of the pathologist to select the areas which are eventually 
embedded, sectioned, stained and analyzed by the most advanced techniques (including 
molecular, genetic, biochemical, etc. methods). The final diagnosis must be discussed at 
MDT sessions and any controversies must be put in the right context vis-á-vis clinical data, 
imaging information and surgical procedure. There is ample evidence to show how therapy 
may change the morphology (and grade) of brain tumours (Molnár and Berényi). 
Experience shows that morphological diagnoses are mostly reliable, problems usually arise 
when the above outlined theoretical and physical limits are neglected, or, in the worst case, 
if the pathologist is inexperienced (which unfortunately often is compensated by over-self-
confidence). Hence the verdict: every patient has the right for and is entitled to a second 
(third?) opinion, should the need arise! These requests must not ever be handled as “vanity” 
issues3. The wisdom of a pathologist is reflected by his humble (but not subservient) attitude 
firstly and outmost towards the patient. The question “Whose tissue is it, after all?” cannot 
be avoided either. Unfortunately with the dawn of tissue collection second opinions are 
often hindered by avaricious motivations of tissue banking and block-anxiety. 
2.4 Biomarkers in neuro-oncology 
In order to indentify the most adequat patient-tailored therapy the pathologist needs to 
identify 3 basic kinds of factors. These comprise diagnostic, prognostic and predictive 
markers. There is a standard but ever growing armamentarium of techniques for achieving 
these goals. Diagnostic markers are those which help to recognize those features which will 
allow the proper WHO classification of the lesion. Traditional histological stains, 
immunohistochemistry (IHC) and certain chromosomal and/or genetic characteristics 
belong to this category. It is mandatory to follow the current literature to realize that certain 
parameters may get moved from the list of one specific kind of markers to another. This is 
well exemplified by the chromosomal change commonly referred to as 1p19q status which 
used to be a predictive marker, nowadays it is one of the most important diagnostic markers 
while having important prognostic significance as well. Prognostic markers are defined as 
such that allow formation of an opinion on the “outlook” of the patient. In other words, 
prognostic markers help to estimate progression free or overall survival of the patient. These 
again may be histological/cytological features (necrosis, proliferative potential) or genetic 
alterations. It has only recently been realized that mutation(s) of the cytoplasmic isocytrate- 
dehydrogenase enzyme, IDH-1/IDH-2 are of prognostic significance in gliomas. Predictive 
markers are those which help to define the most effective treatment for an individual brain 
                                                                 
3 This author has ample personal experience to the contrary! 
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tumor and thus help to avoid the application of ineffective therapeutic interventions which 
would only induce unpleasant and dangerous complications without real therapeutical 
benefit. The most widely studied such marker is the methylation status of the promoter 
region of the MGMT gene (MGMT = methylguanine-methyltransferase). Promoter 
methylation reduces the amount of the enzyme which is encoded by the gene and the 
smaller the amount of this repair enzyme the more effective are the alkylating drugs. 
Recently (BNOS meeting, Cambridge, July 1, 2011) the predictive value of the MGMT status 
has been seriously questioned, although it remains an important prognostic marker. It is 
thus important to note that there is an overlap between various members of these 3 groups 
of biological markers.  
3. Molecular and genetic background for biomarkers 
3.1 Neuroepithelial tumors 
In hindsight it seems rightful to say that the work which started with the identification of 
altered clinical behavior of oligodendroglial tumors with 1p19q co-deletions erupted in an 
unprecedented way once the study of 206 GBM’s genome was published. One can 
confidently state that a new era in neuro-oncology started with the identification of the 3 
major signalling pathways [RTK/RAS/PI(3)K (88%), p53 (87%) and Rb (78%)]. Analysis of 
DNA copy numbers, gene-expression profiles and DNA-methylation patterns provided a 
whole new perspective for the proper evaluation of the real role of ERBB2, NF1 and TP53 
genes. Frequent mutations of PIK3R1 have also been observed. The promoter methylation 
of the MGMT gene acquired unequivocal and clinically fundamental importance. It is now 
accepted that in treated cases of GBM the surfacing hypermutator phenotype is due to 
„mismatch repair deficiency”. 
Mutations may cause primer sequence-alterations, may be indicated by copy number 
changes and evidently may cause activation (gene amplification or overexpression) of 
oncogenes or inactivation (chromosomal loss or gene deletions) of tumor suppressor genes. 
The data published in Nature summarize the analysis of 97 million base pairs that is the 
somatic mutations of 601 genes. It became obvious that in GBMs with NF1 mutations RAF 
or MEK inhibitors may be effective, while CDK inhibitors may prove useful in tumors with 
CDKN2A or CDKN2C mutated GBMs. 
Parsons et al published data on amplification and/or deletion patterns of 20.661 protein 
coding genes in 22 human GBMs. New methodologies (aCGH, high density oligonucleotide 
arrays, next generation sequencing technologies, single nucleotide genomics, massively 
parallel DNA resequencing) reconfirmed their most unexpected result: the earliest genetic 
change in most glial tumors affects the gene that encodes the active site of the cytoplasmic 
form of a carbohydrate-metabolizing enzyme, i. e., IDH = isocytrate dehydrogenase. The 
enzyme has several isoforms but now it is accepted that IDH-1 mutations are the most 
common in relatively young patients’ secondary GBMs which have a better prognosis. The 
results have been confirmed by Blass et al, and Yan et al. and it has also been amply shown 
that IDH-1 mutations are highly specific for glial tumors, they do not occur in systemic 
forms of malignant diseases (certain types of AML are exceptions to the rule). Zhao et al 
published their observations in 2009 which showed that the mutations (IDH-1; R132 or IDH-
2; R172) reduce the enzyme’s affinity towards its substrate plus inactive heterodimers 
appear which dominantly block the activity of the WT IDH-1 activity. There is a 
simultaneous induction of HIF-1┙. A prime role was played in this work by Professor von 
www.intechopen.com
 Classification of Primary Brain Tumors: Molecular Aspects 17 
Deimling and his co-workers in Heidelberg who not only showed (by direct gene-
sequencing) that the IDH-1 mutation is missing from pilocytic astrocytomas but were also 
able to identify a BRAF-KIAAA1549 gene fusion which characterizes these tumors. Thus the 
Heidelberg group for the first time made it routinely possible to separate not only reactive 
astrocytes from neoplastic ones (reactive cells are IDH-1 negative with the commercially 
available antibody which they generated) but also solved the haunting problem of reliably 
identifying pilocytic astrocytomas. 
It is not easy to portray this explosive evolution that has so basically changed the routine 
approach to glioma diagnostics. It has happened so rapidly that in a recent book on “Neuro-
Oncology” (published by Elsevier as part of the “Blue Books of Neurology series in 2010) 
only one (yes, only 1) vague sentence is included on the importance of IDH-1 mutations. 
Meanwhile, in 2011, there is a general agreement amongst neuro-oncopathologists that a 
treatment-determining routine of glioma diagnostics should include the analysis of IDH-1 
mutations (immunohistochemistry), checking of the 1p19q status (FISH) and the mutations 
of TP53 (p53 IHC). These three steps are the minimum “must” for adequate diagnoses. 
The following salient facts support the statement above. Except for the relatively rare 
primary GBMs it seems that the first step in glioma-genesis is the IDH-1 mutation. If that is 
followed by the damage of the 1p19q regions then oligodendrogliomas or oligoastrocytic 
tumors develop. If contrarily, not the 1p19q loci are altered but the TP53 gene is mutated, 
then progression to secondary GBM is inevitable. 
We currently think that primer (de novo) GBMs arise from a different progenitor (TIC) cell 
than all other gliomas, moreover, those genetic alterations which accumulate during the 
biological progression of the various neoplasms which belong to either group are also 
different. These differences obviously have an effect on the proper choice of tailored therapy 
protocols. 
The intrinsic significance of IDH-1 mutations is explained by the fact that this cytoplasmic 
enzyme is a key element in lipid-synthesis, most likely is a regulator of stress-provoked 
protective mechanisms, definitely is an important factor in oxidative cellular mechanisms 
and as such functions as an important player in oxygen-sensor transduction signalling. The 
question whether it is or it is not 2HG (2-hydroxyglutarate; which is a metabolite of the 
IDH-catalyzed metabolic events) that interferes with cellular processes and thus induces 
neoplasms awaits further studies and eventual clarification. 
It is truly amazing to experience the molecular revolution that has recently changed our 
concepts about glioma genesis. This process is in the making, as this chapter is being 
formulated. A very recent publication proves that despite rather similar phenotypic features 
anaplastic oligodendroglial tumors are biologically and clinically heterogeneous. NB. The 
problem of classifying and diagnosing oligodendroglial tumors solely based on 
cytomorphology or immunohistochemistry has been a problem that has haunted neuro-
oncopathologists for a long time (just remember an elusive and highly subjective category: 
glioblastomas with a significant oligodendroglial component). Idbaih et al reported that 
thirty-three BACs (Bacterial Artificial Chromosome array) with prognostic value were 
identified which helped to separate 4 genomic subgroups of anaplastic oligodendroglial 
tumors (AOTs). Type I tumors (25%) also displayed EGFR amplification, higher rate of 
necrosis and were associated with poor prognosis. Type II tumors were usually frontal 
tumors with the well known 1p19q loss and also had the usual oligodendroglial appearance. 
These patients (21.7%) had a longer survival. Type III tumors (11.7%) were characterized 
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with deletion of prognostic BACs (21q) and had short survival. Type IV tumors are defined 
negatively by the absence of the genomic abnormalities seen in the other 3 groups and this 
represents 42% of all tumors. It is seriously thought-provoking that this material was 
comprised of samples of an EORTC trial, meaning, that all tumors were centrally reviewed 
and validated. What else could more convincingly illustrate the preceding paragraphs on 
analogous thinking and the issues related to subjectivity of pathological diagnoses? 
Regardless of some uncertainties associated with this series it is beyond doubt that soon we 
will see the overwhelming need of molecular sub-classification(s) of brain tumors which will 
be prerequisite for tailored therapy. 
A similar tendency is present with regard to GBMs. Based on molecular analyses already in 
2006 GBMs were sub-typed as mesenchymal and proneural. There was one group with a 
high number of CD133+ cells, with relatively sharp demarcation, cortical location. The lack 
of a high number of CD133+ cells was associated with a more expressed angiogeneic and 
proliferative activity. Verhaak et al continued the analysis and currently GBMs seem to 
belong to 4 subtypes: “classic”, mesenchymal, proneural and neural. What is of outmost 
importance is that the canonical Stupp protocol seems to be effective only in the classic and 
mesenchymal subtypes. There is no further need to convince anyone that tailored, 
personalized, individual brain tumor therapy will very soon be more dependent upon 
molecular/genetic features than on traditional tinctorial and immunohistochemical profiles. 
Another recently recognized and increasingly significant observation concerns epigenetic 
features (hyper-, and hypomethylation) as well as the rapidly growing information on 
miRNAs’ regulatory effects. Suffices to say though that the various molecular analyses 
cannot replace traditional morphology: the proper candidates for the adequate molecular 
tests will for a long time to come be chosen based on something like the WHO classification. 
This is demonstrated in Table 4. Entities are still being identified based on pattern 
recognition (i. e., traditional analogous thinking). 
 
Glioma type 
Genomic abnormality 
WHO 
grade 
BRAF 1p19q IDH1 MGMT
alteration deletion mutation methylation 
pilocytic 
astrocytoma 
+ neg neg neg I 
oligodendroglioma neg + + + II 
anaplastic ODG neg + + + III 
oligoastrocytoma 
OA 
neg + + + II 
anaplastic OA neg + + + III 
diffuse 
astrocytoma 
neg neg + + II 
anaplastic 
astrocytoma 
neg neg + + III 
Secondary GBM neg neg + + IV 
Primary GBM neg neg + + IV 
Table 4. 
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Based upon the data in Table 4 it is obvious that state-of-the-art neuro-oncopathology is 
inconceivable without those analyses which are indicated in green. Lack of these results is 
highly counterproductive when it comes to tailored therapy and easily results in inadequate 
(or even harmful) chemotherapy. 
It cannot be overemphasized that the various markers’ definition and their clinical 
significance must from this time on serve as mental charts for neuro-oncologists, much more 
than the minute descriptions of morphological features. However, the latter are still of 
outmost importance for the pathologists, and these are easily accessible (a list of relevant 
reference books are found at the end of the chapter). 
It is disappointing that ependymal tumors en masse show a much less well established list of 
easily detectable, well controlled, prospectively analyzed markers of either diagnostic 
and/or prognostic value. Recent data indicate that 3 groups of ependymomas might be 
possible to separate which do have significantly different survival rates. The best faring 
patients (Group 1; almost 100% 5-year overall survival: OS) suffered from tumors which 
were characterized by gains of chromosome 9, 15q, and/or 18, plus loss of chromosome 6. 
Group 2 patients with a 5-year OS around 70% had mostly diploid genome. Group 3 
patients harbored ependymomas with the worst prognosis (5-year OS less than 30%) 
showed 1q gain and/or homozygous deletion of 9p21. It is important to note that often the 
actual chromosomal portion’s function which is involved is not as yet clarified. Suffice it to 
say here that even for this highly elusive group of tumors there is light at the end of the 
tunnel and based on the recent past it can be expected that multicenter collaborative work 
on these entities will bring highly awaited results. 
3.2 Embryonal tumors 
Parallel to the evolution of molecular markers for gliomas a similar and fundamental change 
has occurred with regard to some embryonal tumors, namely, medulloblastomas. Similarly to 
those that apply to gliomas most of the required analyses are available for not only major 
centers but also for smaller laboratories, mainly due to the availability of immunohistochemical 
methods (i. e., proper and reliably tested antibodies: IDH-1, ┚-catenin, etc.) 
Recent results indicate that medulloblastomas are highly heterogeneous and complex 
neoplasms, which require tailored treatment. Unfortunately on a daily basis therapeutic 
decisions for these patients are still predominantly made on risk group assignment based on 
clinical parameters and histological assessment takes place mainly of end stage disease. It is 
encouraging however, that our understanding of the molecular pathways involved in the 
pathogenesis of the majority of embryonal neoplasms is rapidly increasing. As in the case of 
systemic malignancies (breast-, lung-, colon cancer, and melanoma) molecular profiling of 
individual cancer reflects the individuality of each tumour, reveals the presence or absence 
of distinct disease-associated molecular signatures (see Table 4. and below). Hence these 
data represent a crucial component for the application of new molecular data obtained 
within the realm of basic oncology to tailored clinical practice. 
Molecular subgroups in medulloblastomas (MBs) are characterized by distinct gene 
expression profiles. Convincing presentations at the British Neuro-oncology Society 
(Glasgow, 2010) and at the Salzburg Conference of the ISN (International Society of 
Neuropathology, 2010) plus several rather recent publications attest to the fact that 
activation of the WNT or SHH signalling pathway separates two such subgroups. The 
“WNT subgroup” (cca. 15%) is associated with low-risk disease. New chemotherapeutics are 
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available to target the SHH pathway (SHH subgroup: approximately 30%). Active research 
is going on to further characterize the non-SHH/WNT type of medulloblastoma (more than 
50% of MBs). Commercially available IHC reagents (GAB1, ß-catenin, filamin A, and YAP1 
antibodies) are helpful in distinguishing the various subtypes. 
It is important to realize that MBs originate from cerebellar cortical progenitor cells. The first 
step seems to involve the activation of the WNT and Hedgehog (SHH) pathway. Activation 
of these two signalling pathways leads to the development of “classic” MB, 
nodular/desmoplastic MB and medullomyoblastoma. Accumulation of further genetic 
abnormalities (c-myc and/or N-myc amplification/overexpression, 17p loss, hTERT 
amplification/overexpression, etc.) results in the phenotypic change that characterizes large 
cell/anaplastic MBs. 
Ellison et al reported the IHC classification of medulloblastomas into 3 groups. Their 
modified table is presented below as Table 5. 
 
Pathway 
IHC decoration of 
GAB1 β-catenin Filamin A YAP1 
SHH cytoplasmic (CP) CP CP nuclear + CP 
WNT negative nuclear + CP CP nuclear + CP 
non/SHH/WNT negative CP negative negative 
Table 5. 
Northcott et al have furthered this work and divided the non/SHH/WNT group into 
“Group C” and “Group D”. Their exon array analysis was supplemented with IHC 
detection of the related proteins. The differential expression of 4 genes (DKK1, SFRP1, 
NPR3, and KCNA1) seems to correlate with variability of age groups and risk categories. 
IHC comprised antibodies against ß-catenin, DKK1, SFRP1, GLI1, and KCNA1 proteins. The 
two papers were published during a 2-months-long period within the last six months. This 
only goes to show how rapidly this field is changing. It is to be tested on an ever increasing 
number of patients with proper stratification and statistical analysis but it is already clear 
that at least part of the late and unfortunate consequences of radical chemo- and 
radiotherapy of MBs can be avoided. 
3.3 Meningiomas 
Loss of 22q has long been described in meningeal tumors, however, no prognostic value has 
been possible to link to this alteration which occurs in about 60% of all meningiomas. It is 
important that 1p and 14q deletions are of diagnostic value when the not infrequent issue of 
separating meningiomas from hemangiopericytomas, superficial GBMs or metastatic 
carcinomas is at stake. It is also documented that allelic losses on 1p are characteristic 
features of meningiomas with a higher grade. Probably the most important observation is 
that loss of 14q seems to correlate with not only higher grade but also with an increased 
frequency of recurrence. Our results (Molnár et al. to be published) indicate that ploidy 
measurements combined with nuclear digitized morphometry helps to divide meningiomas 
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basically into two major groups with significantly different tendency to recur or progress 
towards higher grades. 
3.4 Primary CNS lymphomas, PCNSLs 
Statistically the dominant forms are B-cell derived neoplasms. Determination of the proper 
treatment is fundamentally dependent on the results of various IHC reactions. It is notable 
that these data are of both diagnostic-, prognostic- and predictive value. Separation of 
PCNSLs into germinal center type (GC) or postGC/nonGC subtypes has become the 
standard procedure. The most widely used IHC panel is comprised of CD10, CD20, Bcl-6, 
IRF4/MUM1 antibodies. Details of data interpretation are discussed adequately in various 
handbooks/textbooks on the neoplasms of the hematopoietic-lymphoid tissues. 
It is to be kept in mind that the distinctive capillary types of brain tumours (BTB = blood-
tumour barrier [Schlageter et al]) have a unique feature in PCNLs: endothelial cells tend to 
undergo apoptosis as a result of steroid treatment (Molnár et al). 
3.5 Metastatic tumors 
An often encountered problem is that systemic cancers often present themselves as brain – 
or less frequently – spinal cord metastases. The thorough discussion of all problems related 
to clarifying the exact origin of MCUPs (metastatic cancer of unknown primary) exceeds the 
limits of this chapter. 
4. Concluding remarks 
1. Traditional histotechniques continue to provide the basis for starting to evaluate 
neurosurgical samples of neoplastic disease of the CNS. 
2. If the lesion is a glial tumor IDH-1/2 analysis is to be complemented with the 
determination of the 1p19q status and IHC analysis of p53. 
3. If the tumor’s glial nature is equivocal IDH-1/2 IHC should be decisive and needs to be 
complemented by EGFR amplification analysis. If EGFR amplification is present with 
IDH1 mutation then diagnosis of GBM is warranted. 
4. Grade determination might be supported and validated by IDH-1/2 analysis, 1p19q, 
EGFR and p16 FISH. MGMT methylation status is crucial in deciding the actual use of 
already widely available chemotherapeutic protocols (e. g., Stupp’s). 
5. Medulloblastomas already are feasible to stratification into low and high risk 
groups. 
6. Primary CNS lymphomas can be grouped as B or T cell neoplasms and the most 
common type (DLBCL = diffuse large B cell lymphoma) can be separated into GC 
(Germinal Center) types and post GC types with the conventional IHC panels. 
7. Metastatic lesions should be worked up along the lines which are well established in 
systemic pathology. 
Recently, techniques such as next-generation DNA sequencing, massively parallel DNA 
resequencing and 'single-molecule genomics' have revolutionized cancer genomics. The 
results are “pouring in” and we can all expect that these will make a huge impact on 
personalized medicine in the near future. It definitely is an exceedingly exciting time ahead 
and at last neuro-oncopathologists may have positive intellectual reinforcements when 
trying to integrate this information into a morpho-functional interpretation. 
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